Hospira to address misconceptions in EU Remicade biosimilar market
This article was originally published in Scrip
Hospira’s VP Biologics Paul Greenland says the company can become a leader in the infliximab market following its trail-blazing EU approval for a biosimilar monoclonal antibody. It will mobilize lessons already learned from its existing biosimilar products, such as ensuring that doctors don’t swallow peddled misconceptions about biosimilars. And, at least for the time being, the company is not discussing any radical plans to build on its first-mover advantage.
You may also be interested in...
Brazil’s medicines regulator, ANVISA, finally has a new set of rules for the evaluation and marketing authorization of advanced therapy medicines.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.